D S Alberts
Overview
Explore the profile of D S Alberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
367
Citations
4945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Xu X, Wong W, Goldberg L, Baer S, Wolf J, Ramsdell W, et al.
Cancer Res
. 2001 Jun;
61(11):4306-10.
PMID: 11389049
Retinoids are essential for normal skin growth, differentiation, and apoptosis and are active pharmacologically in the prevention and treatment of skin cancers and other lesions. Retinoid effects are mediated mainly...
22.
Alberts D, Hallum 3rd A, Garcia D, Salmon S, Santabarbara P, Niesor E, et al.
Clin Cancer Res
. 2001 May;
7(5):1246-50.
PMID: 11350890
Purpose: To study the human pharmacokinetics and in vitro cytotoxicity of Apomine, an p.o. administered, nonmyelosuppressive agent that selectively inhibits cell proliferation and induces tumor cell apoptosis through the farnesoid...
23.
GARCIA F, Davis J, Alberts D, Hatch K, Weyn B, Thompson D, et al.
Anal Quant Cytol Histol
. 2001 May;
23(2):144-50.
PMID: 11332081
Objective: To characterize the nuclei of endometrial lesions for the diagnostic categories of normal glandular tissue, simple hyperplasia, atypical hyperplasia and adenocarcinoma of the endometrium, with the specific goal of...
24.
Dorr R, Liddil J, Sami S, Remers W, Hersh E, Alberts D
Anticancer Drugs
. 2001 Apr;
12(3):213-20.
PMID: 11290869
The azonafides are a series of anthracene-based DNA intercalators which inhibit tumor cell growth in vitro at low nanomolar concentrations and are not affected by the multidrug resistance phenomenon (MDR)....
25.
Foote J, Harris R, Giuliano A, Roe D, MOON T, Cartmel B, et al.
Int J Cancer
. 2001 Mar;
95(1):7-11.
PMID: 11241303
Risk factors for non-melanoma skin cancer among populations with evidence of precursor damage are not well described. We examined and compared risk factors associated with the development of cutaneous basal-cell...
26.
Bartels P, GARCIA F, Davis J, da Silva V, Bartels H, Thompson D, et al.
Anal Quant Cytol Histol
. 2001 Mar;
23(1):1-8.
PMID: 11233737
Objective: To derive a numeric measure for the progression of endometrial lesions as a baseline study for an eventual assessment of chemopreventive intervention efficacy. Study Design: Tissue sections from normal...
27.
Chow H, Cai Y, Alberts D, Hakim I, Dorr R, Shahi F, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Feb;
10(1):53-8.
PMID: 11205489
Green tea has been shown to exhibit cancer-preventive activities in preclinical studies. Its principal active components include epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin (EC), and epicatechin gallate, of which EGCG...
28.
Markman M, Bundy B, Alberts D, Fowler J, Carson L, Wadler S, et al.
J Clin Oncol
. 2001 Feb;
19(4):1001-7.
PMID: 11181662
Purpose: To compare the progression-free and overall survival in small-volume residual ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an experimental regimen of IV carboplatin followed by...
29.
Calaluce R, Earnest D, Heddens D, Einspahr J, Roe D, Bogert C, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Jan;
9(12):1287-92.
PMID: 11142413
Prostaglandin E2 (PGE2) has served as a surrogate end point biomarker in colorectal tumor progression. Colonic mucosa PGE2 levels of patients with colorectal adenomas or carcinomas have been shown to...
30.
Alberts D, Dorr R, Einspahr J, Aickin M, Saboda K, Xu M, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Jan;
9(12):1281-6.
PMID: 11142412
Alpha-2-(Difluoromethyl)-dl-ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, has been shown to suppress skin carcinogenesis in murine models after oral or topical administration. We designed a randomized, placebo-controlled study using...